Evaluación de la efectividad de una intervención para la deprescripción de la aspirina en prevención primaria de la enfermedad cardiovascular
- 18 February 2026
- journal article
- abstracts
- Published by Elsevier in Medicina de Familia. SEMERGEN
- Vol. 52 (3) , 102696
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Understanding potentially inappropriate medication: A focus group study with general practitionersInternational Journal of Medical Informatics, 2025
- Aspirin Use to Prevent Cardiovascular DiseaseJAMA, 2022
- Evaluation of prophylaxis in primary prevention with acetylsalicylic acid in people with diabetes: A scoping reviewMedicina de Familia. SEMERGEN, 2022
- Aspirin for cardiovascular disease prevention among adults in the United States: Trends, prevalence, and participant characteristics associated with useAmerican Journal of Preventive Cardiology, 2021
- 2021 ESC Guidelines on cardiovascular disease prevention in clinical practiceEuropean Heart Journal, 2021
- Aspirin for Primary Prevention of Cardiovascular EventsJACC, 2019
- Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding EventsJAMA, 2019
- Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy ElderlyNew England Journal of Medicine, 2018
- Effects of Aspirin for Primary Prevention in Persons with Diabetes MellitusNew England Journal of Medicine, 2018
- Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trialThe Lancet, 2018